RxDoctor Payments Data

David Feifel, MD

Psychiatry · la Jolla, CANPI 1053467738

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Johnson & Johnson at 56.9% of the total. Reporting peaked in 2019 at $5,945 and has fallen 99.5% since, to $28 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,180in general payments, 2019–2025

Across 21 payments — averaging $294.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Brainsway USA Inc$3K
  • Livanova USA, Inc.$73
$3,400in research payments, 2019–2025

Across 1 payment — averaging $3400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Brainsway USA Inc$3K

What the payments were for

  • Speaking & faculty fees$2,25036%
  • Travel & lodging$77112%
  • Food & beverage$3,15951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson15$3,517
Brainsway USA Inc3$2,590
Livanova USA, Inc.3$73

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,180 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$155,720
Medicare patients
60
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl23$28,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$3,517$28,06023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →